Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient

被引：2
作者：
Ghosn, Marwan [1 ]
Dagher, Alain [1 ]
El-Karak, Fadi [1 ]
机构：
[1] St Joseph Univ, Dept Hematol Oncol, Fac Med, 894 Blvd Alfred Naccache,Bldg Sehanoui,5th Floor, Beirut, Lebanon
来源：
JOURNAL OF BIOMEDICAL RESEARCH | 2015年 / 29卷 / 05期
关键词：
prostate-specific antigen; doubling time; prostate cancer; cabazitaxel; docetaxel;
D O I：
10.7555/JBR.28.20130148
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value. The prostate-specific antigen doubling time was found to be a good response predictor in the patient.
引用
收藏
页码：420 / 422
页数：3
相关论文
共 50 条
  • [21] Value of mitoxantrone in hormone-resistant metastatic prostate cancer.
    Khalaf, A
    Pfister, C
    Hellot, MF
    Dunet, F
    Moussu, J
    Grise, P
    [J]. PROGRES EN UROLOGIE, 2002, 12 (01): : 37 - 42
  • [22] Critical analysis of prostate-specific antigen doubling time calculation methodology
    Svatek, RS
    Shulman, M
    Choudhary, PK
    Benaim, E
    [J]. CANCER, 2006, 106 (05) : 1047 - 1053
  • [23] A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
    Noguchi, Masanori
    Moriya, Fukuko
    Suekane, Shigetaka
    Ohnishi, Rei
    Matsueda, Satoko
    Sasada, Tetsuro
    Yamada, Akira
    Itoh, Kyogo
    [J]. BMC CANCER, 2013, 13
  • [24] Metastatic prostate cancer (with prostate-specific antigen of 9996) presenting as obstructive jaundice
    Cole, A
    Mendelblatt, D
    Aguayo, J
    Mathew, A
    Martin, E
    Vesely, DL
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2000, 319 (02) : 118 - 122
  • [25] Utility of Prostate-Specific Antigen Isoforms and Prostate Health Index in the Diagnosis of Metastatic Prostate Cancer
    Raju, Govinda Nanjaiah Laxmana
    Bhat, Parineetha P.
    Nagini, Siddavaram
    [J]. JOURNAL OF LABORATORY PHYSICIANS, 2023, 15 (02) : 237 - 242
  • [26] TUMOR-MARKER DOUBLING TIME IN PATIENTS WITH PROSTATE-CANCER - DETERMINATION OF PROSTATE-SPECIFIC ANTIGEN AND PROSTATIC ACID-PHOSPHATASE DOUBLING TIME
    AKIMOTO, S
    MASAI, M
    AKAKURA, K
    SHIMAZAKI, J
    [J]. EUROPEAN UROLOGY, 1995, 27 (03) : 207 - 212
  • [27] Midlife baseline prostate-specific antigen, velocity, and doubling time association with lethal prostate cancer and mortality
    Cirulli, Giuseppe Ottone
    Davis, Matthew
    Stephens, Alex
    Chiarelli, Giuseppe
    Finati, Marco
    Chase, Morrison
    Tinsley, Shane
    Arora, Sohrab
    Sood, Akshay
    Lughezzani, Giovanni
    Buffi, Nicolo
    Carrieri, Giuseppe
    Salonia, Andrea
    Briganti, Alberto
    Montorsi, Francesco
    Rogers, Craig
    Abdollah, Firas
    [J]. CANCER, 2025, 131 (01)
  • [28] Racial differences in prostate-specific antigen levels and prostate-specific antigen densities in patients with prostate cancer
    Abdalla, I
    Ray, P
    Ray, V
    Vaida, F
    Vijayakumar, S
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (06): : 537 - 541
  • [29] Chemotherapy in early stage of hormone-resistant metastatic prostate cancer: what are the indications?
    Drouin, S. J.
    Roupret, M.
    Wallerand, H.
    Houede, N.
    [J]. PROGRES EN UROLOGIE, 2010, 20 : S192 - S197
  • [30] Metastatic prostate cancer with normal level of serum prostate-specific antigen
    R. Nishio
    Y. Furuya
    O. Nagakawa
    H. Fuse
    [J]. International Urology and Nephrology, 2003, 35 (2) : 189 - 192
12345